Chronic hepatitis C in the aged: Much ado about nothing or nothing to do?

Drugs and Aging

Volumn 31, Issue 5, 2014, Pages 339-347

  Malnick, Stephen ^a   Maor, Yaakov ^a   Melzer, Ehud ^a   Tal, Sari ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; BOCEPREVIR; CYANOCOBALAMIN; HEPATITIS C ANTIBODY; INSULIN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; VITAMIN D;

AGE; AGED; AGING; ANOREXIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BABY BOOMER; BLOOD TRANSFUSION; BODY MASS; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG APPROVAL; DRUG INTERACTION; ECHOGRAPHY; ELASTOGRAPHY; ETHNICITY; EVIDENCE BASED MEDICINE; FATIGUE; FATTY LIVER; FOOD AND DRUG ADMINISTRATION; GENDER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; LIVER TRANSPLANTATION; MIXED INFECTION; MORBIDITY; MYALGIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SUSTAINED VIRAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VITAMIN SUPPLEMENTATION; WEAKNESS; WEIGHT REDUCTION; HEPATITIS C, CHRONIC;

AGE FACTORS; AGED; HEPATITIS C, CHRONIC; HUMANS;

EID: 84900825422     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0170-8     Document Type: Article

References (66)

1. Topinková E, Baeyens JP, Michel J-P, Lang P-O. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;1(29):477-94.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
3. Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the centers for disease control and prevention. Ann Intern Med. 2012;157:817-22.
4. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(suppl 2):13-25.
5. Rosen H. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429-38.
6. Crome P, Natarajan I. The National Service Framework for Older People: England's approach to ending age discrimination in services and therapeutics. Drugs Aging. 2004;21:499-510.
7. Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57:881-9.
8. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. The vertical transmission of hepatitis C virus collaborative study group. N Engl J Med. 1994;330:744-50.
9. Geerlings W, Tufveson G, Ehrich JH, et al. Report on management of renal failure in Europe XXIII. Nephrol Dial Transplant. 1994;9(suppl 1):6-25.
10. Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis. 2011;31:340-6.
11. Chien NT, Dundoo G, Horani MH, et al. Seroprevalence of viral hepatitis in an older nursing home population. J Am Geriatr Soc. 1999;47:1110-3.
12. Monica F, Lirussi F, Pregun I, et al. Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study. Dig Liver Dis. 2006;38:336-40.
13. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology. 2009;49:676-88.
14. González-Peralta RP, Qian K, She JY, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol. 1996;49:242-7.
15. El-Serag HB,Davila JA, Petersen NJ,McGlynn KA.The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;18(139):817-23.
16. Wiese M, Grüngreiff K, Güthoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study. J Hepatol. 2005;43:590-8.
17. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-9.
18. Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53:451-5.
19. Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med. 1993;86:119-25.
20. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005;41:801-8.
21. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156:263-70.
22. Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26(3 Suppl 1):43S-7S.
23. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology. 2007;46:22-31.
24. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93.
25. Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int. 2011;31(Suppl 1):13-7.
26. Jacobson IM, Pawlotsky J-M, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012;19:1-26.
27. Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748-55.
28. Bresci G, Del Corso L, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCVpositive chronic active hepatitis. J Am Geriatr Soc. 1993;41:857-62.
29. Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol. 1995;10:246-9.
30. Van Thiel DH, Friedlander L, Caraceni P, et al. Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci. 1995;50:M330-3.
31. Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med. 2003;11:208-12.
32. Koyama R, Arase Y, Ikeda K, et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2006;49:121-6.
33. Honda T, Katano Y, Urano F, et al. Efficacy of ribavirin plus interferon-alpha in patients aged ≥60 years with chronic hepatitis C. J Gastroenterol Hepatol. 2007;22:989-95.
34. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol. 2004;39:1069-77.
35. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50:16-23.
36. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006;43:54-63.
37. Tsui JI, Currie S, Shen H, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 study. Dig Dis Sci. 2008;53:809-14.
38. Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc. 2006;54:549-50.
39. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol. 2007;102:1383-91.
40. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol. 2006;101:1260-7.
41. Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol. 2006;20:589-92.
42. Kainuma M, Furusyo N, Kajiwara E, et al. Pegylated interferon α-2b plus rubavarin for patients with chronic hepatitis C. World J Gastroenterol. 2010;16:4400-9.
43. Gramenzi A, Conti F, Cammà C, et al. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis. 2012;44:674-80.
44. Hu C-C, Lin C-L, Kuo Y-L, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther. 2013;37:81-90.
45. Frei P, Leucht AK, Kofmehl R et al. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis c virus patients. Liver Int 2013. doi:10.1111/liv.12279.
46. Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans affairs Hepatitis C resource center program and the National hepatitis C Program office. Am J Gastroenterol. 2012;107:669-89.
47. Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205-12.
48. Moreno C, Wedemeyer H, Fernandez I, et al. Efficacy and safety results of treatment of patients over 65 years old with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis: the International Telaprevir Early Access Program. Hepatology. 2013;58(4(suppl)):186 A (Abstract 1911).
49. Hezode C, Fontaine H, Dufour C, et al. Efficacy and safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavarin in cirrhotics according to the age. Data from the CUPIC cohort (ANRS C020). Hepatology. 2013;58(4(suppl)):181A (Abstract 1845).
50. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87.
51. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir (TMC435) with peginterferon/ribavarin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver. April 24-28, 2013. Amsterdam, The Netherlands Abstract 1425.
52. Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. Presented at the 48th annual meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, April 24-28, 2013. Abstract 1413.
53. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;6:361580-93.
54. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int. 2009;29(Suppl 1):15-8.
55. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27:2444-9.
56. Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease - a common and benign finding in octogenarian patients. Liver Int. 2004;24:588-94.
57. Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011;21(17):5184-90.
58. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol. 2012;18:800-5.
59. Houston DK, Tooze JA, Davis CC, et al. Serum 25-hydroxyvitamin D and physical function in older adults: the Cardiovascular Health Study All Stars. J Am Geriatr Soc. 2011;59:1793-801.
60. Rocco A, Compare D, Coccoli P, et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut. 2013;62:766-73.
61. Burger D, Back D, Buggisch P et al. Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. J Hepatol. doi:10.1016/j.jhep.2012.10.027.
62. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;2012(60):616-31.
63. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-21.
64. American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. J Am Geriatr Soc. 2012;60(10):E1-25.
65. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for the elderly:the effect of competing risks. Ann Intern Med. 1996;124:577-84.
66. United States Life Tables 2009, National Vital Statistics Reports 2014;62(7).